T-Cell Immunotherapy, A Novel Advancement For The Treatment Of Cancer

The T cell immunotherapy exhibits strong pipeline with estimated 139 drug candidates in 2016.

T-cell immunotherapy pipeline in 2016

The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates, of which 16 are in Phase II stage of development. The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer. It is gaining huge traction globally, for its several advantages over conventional therapies such as very low or no side effects and high specificity.

Browse the Report Summary at: www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis

Insights on pipeline segments

As per the findings of research, it was found that around 22% T-cell immunotherapeutic candidate target CD19, and 6% target Prostate Specific Membrane Antigen (PSMA) and Prostate Stem Cell Antigen(PSCA). Around 62% pipeline therapeutic candidates of T-cell immunotherapy are being administered by intravenous route, 19% drugs are administered by parenteral route, 15% therapeutic candidates are administered by infusion route.

Chimeric antigen receptors (CAR) T-cell is majorly researched and developed, representing 75% T-cell immunotherapeutic candidates

CAR T-cells are the modified T-cells used to express CARs, which recognize specific antigens present on targeted cell. CARs are specifically designed synthetic receptors, linked with the single-chain variable fragment (scFV) of a monoclonal antibody. The domain includes T-cell receptor CD3-zeta chain, which graft specificity into an immune effector cell. It mediates T-cell cytotoxicity and activation when bound to a target cell.

Explore Report Sample at: www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis/report-sample

Phase II, highest stage of development for T-cell immunotherapy

A total of 16 products are in Phase II stage, of which KTE-C19, anti-CD19 CAR T therapy of Kite Pharmaceuticals initiated to enroll submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Tisagenlecleucel-T, also known as CTL019 CART-19, is under Phase II stage of development by Novartis Pharmaceuticals for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma and non-Hodgkin’s lymphoma. U.S. FDA granted breakthrough therapy designation to CTL019 for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia in July 2014. The breakthrough therapy filing was submitted by the University of Pennsylvania's Perelman School of Medicine, which has an exclusive global agreement with Novartis to research, develop and commercialize personalized CAR T-cell therapies for the treatment of cancers.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016

This release was published on openPR.